MRKR
Marker Therapeutics, Inc. SEC filings
Every EDGAR filing for Marker Therapeutics, Inc. (MRKR), newest first, with AI summaries and stories.
- Ticker
- MRKR
- CIK
- 1094038
- Latest filing
- Aug 14
Next: earnings expected ~Nov 16 · 10-Q expected ~Nov 16 (deadline Nov 16)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
NOTABLE10-QMarker Therapeutics, Inc.MRKRLIVE NOTABLE10-QMarker Therapeutics, Inc.MRKRLIVE ROUTINE8-KMarker Therapeutics, Inc.MRKRLIVE ROUTINEDEFA14AMarker Therapeutics, Inc.MRKRLIVE ROUTINEARSMarker Therapeutics, Inc.MRKRLIVE ROUTINEDEF 14AMarker Therapeutics, Inc.MRKRLIVE NOTABLE10-KMarker Therapeutics, Inc.MRKRLIVE ROUTINEPRE 14AMarker Therapeutics, Inc.MRKRLIVE ROUTINE8-KMarker Therapeutics, Inc.MRKRLIVE ROUTINE4Marker Therapeutics, Inc.MRKRLIVE 3 insider filings
Steve Elms, insider filing for MRKR
Show all 3
- 4Insider filing for MRKR
- 4Insider filing for MRKR
- 4Insider filing for MRKR
Steve Elms, reporting
ROUTINESCHEDULE 13G/AMarker Therapeutics, Inc.MRKRLIVE Alyeska Investment Group, L.P. filed an amended Schedule 13G, disclosing a 5.1% ownership stake in Marker Therapeutics, Inc. (MRKR). This regulatory filing indicates Alyeska's significant investment position in the clinical-stage biopharmaceutical company, which is developing…
Alyeska Investment Group, L.P., filed by
ROUTINE8-KMarker Therapeutics, Inc.MRKRLIVE NOTABLE10-QMarker Therapeutics, Inc.MRKRLIVE Marker Therapeutics, Inc. (MRKR) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational status.
ROUTINE8-KMarker Therapeutics, Inc.MRKRLIVE ROUTINE4Marker Therapeutics, Inc.LIVE 3 insider filings
Kathryn Penkus Corzo, insider filing for Marker Therapeutics, Inc.
Show all 3
- 4Insider filing for Marker Therapeutics, Inc.
- 4Insider filing for Marker Therapeutics, Inc.
- 3New insider at Marker Therapeutics, Inc.
Kathryn Penkus Corzo, reporting